Warmuth Markus 4
4 · Monte Rosa Therapeutics, Inc. · Filed Apr 15, 2026
Research Summary
AI-generated summary of this filing
Monte Rosa CEO Markus Warmuth Sells 8,000 Shares
What Happened
Markus Warmuth, President & CEO and a director of Monte Rosa Therapeutics (GLUE), sold 8,000 shares on April 14, 2026. The filing reports a weighted average sale price of $17.64 per share for total proceeds of $141,125. This was a sale (disposition) — sales are often routine liquidity events and do not necessarily indicate a change in company prospects.
Key Details
- Transaction date: 2026-04-14 (reported on Form 4 filed 2026-04-15).
- Price: weighted average $17.64 per share; individual trades ranged $17.64–$17.65 (see footnote).
- Quantity: 8,000 shares sold; proceeds reported as $141,125.
- Shares owned after the transaction: not disclosed in the information provided in this summary (see the Form 4 for full beneficial ownership).
- Footnote: the Column 4 price is a weighted average; the filer will provide breakdown of sales at each price on request.
- Timeliness: filing appears timely (filed one day after the reported transaction date).
Context
This was an outright sale (S code) reported on a Form 4. For retail investors, purchases generally carry more direct signaling value than routine insider sales, which can reflect diversification or personal financial planning. Check the full Form 4 for any additional holdings, prior 10b5-1 plans, or related transactions that could provide more context.
Insider Transaction Report
- Sale
Common Stock
[F1]2026-04-14$17.64/sh−8,000$141,125→ 605,471 total
Footnotes (1)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.64 to $17.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.